文献速递临床微生物分子诊断临床血液与体液

Accelerate Pheno系统对无菌体液培养阳性瓶的快速鉴定与药敏评估

Evaluation of the Accelerate Pheno System for Rapid Identification and Antimicrobial Susceptibility Testing of Positive Blood Culture Bottles Inoculated with Primary Sterile Specimens from Patients with Suspected Severe Infections.
PubMed 文献 · J Clin Microbiol · 2021-04-20

该研究评估Accelerate Pheno系统(APS)对100例患者无菌非血液标本(脑脊液63份、腹水16份等)培养阳性血培养瓶的鉴定与药敏性能。APS鉴定与常规方法总体符合率72%(72/100培养),仅面板内病原符合率78%(72/92培养);药敏总体分类一致率91.2%,极重大错误率0.2%。APS可加速严重感染患者无菌体液标本的病原鉴定与表型药敏,但多微生物感染可能降低其性能。

要点

  • APS对无菌体液培养阳性瓶的鉴定总体符合率72%,面板内病原符合率78%。
  • APS药敏与常规方法总体分类一致率91.2%,极重大错误率仅0.2%。
  • 多微生物感染中APS与常规方法仅2/9培养(22%)鉴定出全部病原。

核心结论

  • APS可加速严重感染患者无菌体液培养阳性瓶的病原鉴定与表型药敏,尤其适合无现场微生物实验室的医院。
  • 但包含高概率多微生物感染的非血液标本可能导致性能下降。

研究设计与样本

  • 前瞻性评估研究,纳入100例疑似严重感染患者的100份无菌非血液标本培养阳性血培养瓶。
  • 标本类型包括脑脊液63份、腹水16份、胸水7份、玻璃体液4份、关节液5份及其他穿刺液5份。
  • 以常规方法为参考,评估APS的病原鉴定与表型药敏性能。

主要发现

  • APS鉴定与常规方法符合:全部病原时72/100培养(72%)、81/112病原(72%);仅面板内病原时72/92培养(78%)、81/104病原(78%)。
  • APS未鉴定的31株中8株(26%)为面板外病原。
  • 9份多微生物培养中仅2份(22%)APS与常规方法鉴定出全部病原。
  • APS对57份培养的57株病原生成耐药结果,与常规药敏总体分类一致率91.2%。
  • 药敏错误率:次要错误6.9%、重大错误1.7%、极重大错误0.2%。

临床怎么用

  • 对无菌体液培养阳性瓶,APS可快速提供病原鉴定与表型药敏,辅助严重感染早期决策。
  • 需注意APS面板覆盖范围,面板外病原可能无法鉴定。
  • 多微生物感染标本APS性能可能降低,结果需结合常规方法确认。

局限性

  • 纳入标本包含高概率多微生物感染的非血液标本,可能影响APS性能评估的普适性。
  • 原文未报告样本量计算、盲法设计及具体局限性描述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Accelerate Pheno system is approved for rapid identification and phenotypic antimicrobial susceptibility testing (AST) of microorganisms grown from positive blood cultures inoculated with blood from septic patients. We evaluated the performance of the system for identification and AST from positive blood culture bottles inoculated with primary sterile nonblood specimens from patients with suspected severe infections. One hundred positive blood culture bottles with primary sterile specimens (63 cerebrospinal fluids, 16 ascites, 7 pleural fluids, 4 vitreous fluids, 5 joint aspirates, and 5 other aspirates) from 100 patients were included. Pathogen identification was in agreement with conventional methods for 72 of 100 cultures (72%) and for 81 of 112 (72%) pathogens when considering all pathogens and for 72 of 92 (78%) cultures and 81 of 104 (78%) pathogens when considering on-panel pathogens only. Eight of 31 isolates (26%) not identified by APS were pathogens not included in the APS panel. APS and conventional methods accordingly identified all pathogens from two of nine polymicrobial cultures (22%). APS generated antimicrobial resistance results for 57 pathogens of 57 cultures. The overall category agreement between APS and culture-based AST was 91.2%; and the rate for minor errors was 6.9%, for major was 1.7%, and for very major errors was 0.2%. APS may accelerate pathogen identification and phenotypic AST from positive blood culture bottles inoculated with primary sterile specimens from patients with serious infections, especially for hospitals without an on-site microbiology laboratory. However, the inclusion of nonblood specimens with a high likelihood of polymicrobial infections may result in an inferior performance.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Chapot V, Effenberg L, Dohmen-Ruetten J, et al. Evaluation of the Accelerate Pheno System for Rapid Identification and Antimicrobial Susceptibility Testing of Positive Blood Culture Bottles Inoculated with Primary Sterile Specimens from Patients with Suspected Severe Infections. J Clin Microbiol. 2021. PMID: 33568464. doi:10.1128/JCM.02637-20

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。